IGFBP3 and hemoglobin measurement: Nevertheless, technical restrictions, such as heterogeneity of tumor samples, which comprise the stromal components and the adjacent normal liver tissue in low proportions, might have contributed to an underestimation of HB cases with a methylated IGFBP3 promoter in our study.